SciSparc Unit NeuroThera Labs Issues Update On Its Clinical Trial Program Evaluating SCI-110 For Treatment Of Tourette Syndrome In Adults; Now Advancing Toward Patient Enrollment In Its Phase IIb Clinical Trial For TS, With Investigational Product Shipments To Study Sites Expected In The Near Term

SciSparc Reduces Warrant Exercise Price To $1 Per Share In Inducement Agreement; Expects To Receive Aggregate Gross Proceeds Of ~$405,728 From Exercise Of Existing Warrants

Dow Surges Over 200 Points; Verizon Shares Fall Following Q3 Results

U.S. stocks rose Monday, led by the Dow’s 200-point gain. Consumer discretionary rallied, Verizon fell after mixed results, and oil dropped 1.2%.

SciSparc Subsidiary NeuroThera Labs Achieves Regulatory Milestone for Tourette Syndrome Clinical Trial

SciSparc's subsidiary, NeuroThera Labs, has completed manufacturing and obtained batch release certification for its SCI-110 drug candidate, enabling the start of patient enrollment in a Phase IIb clinical trial.

SciSparc shares are trading lower after the company announced a strategic shift toward Agentic AI, cybersecurity, and finance technologies, noting there is no assurance the initiative will generate revenue.

SciSparc Shifts Strategic Focus To Agentic AI Powered Technologies, Including Cybersecurity And Finance Technologies

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.Building

SciSparc shares reversed earlier gains and are now trading lower after the company disclosed an inducement agreement to convert ~$2.02 million of outstanding principal and accrued interest under a convertible promissory note into ordinary shares at $1.50 per share.